Update on the restructuring of the AB Science clinical development department in 2018
19/12/2018 – AB Science provides the main achievements of this restructuring.
Masitinib phase 3 study in Alzheimer’s disease has completed patient recruitment
22/10/2018 – Final results will be available in 2019.
First half of 2018 revenues
01/10/2018 – AB Science reports its revenues for the first half of 2018 and provides an update on its activities.
Positive IDMC recommendation to continue the study based on a trend analysis of the masitinib phase 2/3 study in refractory metastatic colorectal cancer
23/07/2018 – A trend analysis for OS was planned after a certain number of events are observed.
Results of the Combined General Shareholders’ Meeting held on June 29 2018
03/07/2018 – The voting details for each resolution are available in the Investor Relations section of the website.
Combined General Shareholders’ Meeting held on June 29, 2018
03/07/2018 – Presentation of the current situation and future prospects.
Update on EU marketing authorization application for masitinib in the treatment of amyotrophic lateral sclerosis
28/05/2018 – AB Science is evaluating the possibility to resubmit the application based on the final results from study AB10015.
Corporate Presentation
13/03/2018 – Current status and perspective for 2018.
Veterinary Medicine – Oncology
Masitinib scientific data 22/09/2011 – for veterinary medicine n°3 The Veterinary Journal 21/02/2011 – Results from a preclinical study showing that masitinib has potential as a chemosensitizer Masitinib in Mast Cell Tumor – Phase 3 data 02/11/2010 – Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell…
Veterinary Medicine – Inflammatory diseases
Veterinary Research Communications 01/01/2010 – Masitinib for the treatment of canine atopic dermatitis: a pilot study North American Veterinary Dermatology 18/04/2009 – A tyrosine kinase inhibitor targeting c-Kit for chronic inflammatory diseases involving mast cells.